Lawrence A. Leiter

MDCM, FRCPC, FACP, FACE, FAHA

Investigator

Biography

Please note: Dr. Leiter is not taking any summer students.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 500 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas.

Dr. Leiter is the past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and is a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. He also received the 2005 CSEM Educator of the Year Award, and the 2006 CDA Gerald S. Wong Award in recognition of significant contributions to the diabetes community. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.

 

Recent Publications

  1. Bosch, J, Lonn, EM, Jung, H, Zhu, J, Liu, L, Lopez-Jaramillo, P et al.. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. Eur Heart J. 2021; :. doi: 10.1093/eurheartj/ehab225. PubMed PMID:33963372 .
  2. Mosenzon, O, Del Prato, S, Schechter, M, Leiter, LA, Ceriello, A, DeFronzo, RA et al.. From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes. Cardiovasc Diabetol. 2021;20 (1):92. doi: 10.1186/s12933-021-01281-y. PubMed PMID:33910583 PubMed Central PMC8082901.
  3. Kalantar-Zadeh, K, Schwartz, GG, Nicholls, SJ, Buhr, KA, Ginsberg, HN, Johansson, JO et al.. Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial. Clin J Am Soc Nephrol. 2021; :. doi: 10.2215/CJN.16751020. PubMed PMID:33906908 .
  4. Zhou, Z, Jardine, MJ, Li, Q, Neuen, BL, Cannon, CP, de Zeeuw, D et al.. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis. Stroke. 2021;52 (5):1545-1556. doi: 10.1161/STROKEAHA.120.031623. PubMed PMID:33874750 PubMed Central PMC8078131.
  5. Zelniker, TA, Raz, I, Mosenzon, O, Dwyer, JP, Heerspink, HHJL, Cahn, A et al.. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2021; :. doi: 10.1001/jamacardio.2021.0660. PubMed PMID:33851953 PubMed Central PMC8047725.
  6. Nouraei, H, Leiter, LA, Tan, MK, Langer, A, Teoh, H, Cheng, AYY et al.. Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. Can J Diabetes. 2021; :. doi: 10.1016/j.jcjd.2021.02.003. PubMed PMID:33839025 .
  7. Cavallari, I, Bhatt, DL, Steg, PG, Leiter, LA, McGuire, DK, Mosenzon, O et al.. Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial. J Am Coll Cardiol. 2021;77 (14):1837-1840. doi: 10.1016/j.jacc.2021.02.030. PubMed PMID:33832610 .
  8. Pearson, GJ, Thanassoulis, G, Anderson, TJ, Barry, AR, Couture, P, Dayan, N et al.. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2021; :. doi: 10.1016/j.cjca.2021.03.016. PubMed PMID:33781847 .
  9. Wright, RS, Ray, KK, Raal, FJ, Kallend, DG, Jaros, M, Koenig, W et al.. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021;77 (9):1182-1193. doi: 10.1016/j.jacc.2020.12.058. PubMed PMID:33663735 .
  10. Cahn, A, Raz, I, Leiter, LA, Mosenzon, O, Murphy, SA, Goodrich, EL et al.. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care. 2021; :. doi: 10.2337/dc20-2492. PubMed PMID:33653824 .
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto
X